Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM

被引：1
|
作者：
Kaneto, Hideaki
Takami, Akane
Spranger, Robert
Amano, Atsushi
Watanabe, Daisuke
Niemoeller, Elisabeth
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1032-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1032-P
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L Trial
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Galvez, Guillermo Gonzalez
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES, 2016, 65 : A62 - A63
  • [2] Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Elderly Patients with T2D
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Frias, Juan Pablo
    [J]. DIABETES, 2016, 65 : A246 - A246
  • [3] Efficacy and Safety across the Final Dose Ranges in Patients with T2DM Receiving Insulin Glargine/Lixisenatide Fixed-Ratio Combination in the LixiLan-L Trial
    Ritzel, Robert
    Vidal, Josep
    Aroda, Vanita R.
    Wu, Yujun
    Souhami, Elisabeth
    Niemoeller, Elisabeth
    Henry, Robert R.
    [J]. DIABETES, 2016, 65 : A266 - A267
  • [4] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    [J]. DIABETES, 2014, 63 : A87 - A88
  • [5] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Frias, Juan P.
    Dex, Terry
    Roberts, Michelle
    Kaplan, Allen
    [J]. DIABETES THERAPY, 2019, 10 (01) : 21 - 33
  • [6] Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Niemoeller, Elisabeth
    Frias, Juan Pablo
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (03) : 236 - 242
  • [7] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Juan P. Frias
    Terry Dex
    Michelle Roberts
    Allen Kaplan
    [J]. Diabetes Therapy, 2019, 10 : 21 - 33
  • [8] iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup Analysis
    Russell-Jones, David
    Mccrimmon, Rory J.
    Barber, Thomas M.
    Baradez, Cecile
    Baxter, Michael A.
    Davies, Melanie
    [J]. DIABETES, 2017, 66 : LB35 - LB35
  • [9] Titratable fixed-ratio vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on basal insulin
    Meier, J. J.
    Vidal, J.
    Liu, M.
    Perfetti, R.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2017, 60 : S372 - S372
  • [10] Shorter Time to Glycemic Control with Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Compared with Insulin Glargine Treatment Alone
    Frias, Juan P.
    Domingo, Manuel Puig
    Meneghini, Luigi F.
    Nap-Oli, Raffaele
    Liu, Minzhi
    Rak, Erika Soltes
    Aroda, Vanita R.
    [J]. DIABETES, 2017, 66 : A287 - A287
12345